140 related articles for article (PubMed ID: 26680649)
1. New concept: cellular senescence in pathophysiology of cholangiocarcinoma.
Sasaki M; Nakanuma Y
Expert Rev Gastroenterol Hepatol; 2016; 10(5):625-38. PubMed ID: 26680649
[TBL] [Abstract][Full Text] [Related]
2. Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma.
Sasaki M; Matsubara T; Kakuda Y; Sato Y; Nakanuma Y
Am J Surg Pathol; 2014 Mar; 38(3):364-9. PubMed ID: 24487593
[TBL] [Abstract][Full Text] [Related]
3. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.
Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863
[TBL] [Abstract][Full Text] [Related]
4. The molecular pathogenesis of cholangiocarcinoma.
Berthiaume EP; Wands J
Semin Liver Dis; 2004 May; 24(2):127-37. PubMed ID: 15192786
[TBL] [Abstract][Full Text] [Related]
5. Bile duct expression of pancreatic and duodenal homeobox 1 in perihilar cholangiocarcinogenesis.
Igarashi S; Matsubara T; Harada K; Ikeda H; Sato Y; Sasaki M; Matsui O; Nakanuma Y
Histopathology; 2012 Aug; 61(2):266-76. PubMed ID: 22594685
[TBL] [Abstract][Full Text] [Related]
6. In Vivo Models for Cholangiocarcinoma-What Can We Learn for Human Disease?
Mohr R; Özdirik B; Knorr J; Wree A; Demir M; Tacke F; Roderburg C
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679791
[TBL] [Abstract][Full Text] [Related]
7. Polycomb group protein Bmi1 is overexpressed and essential in anchorage-independent colony formation, cell proliferation and repression of cellular senescence in cholangiocarcinoma: tissue and culture studies.
Sasaki M; Yamaguchi J; Ikeda H; Itatsu K; Nakanuma Y
Hum Pathol; 2009 Dec; 40(12):1723-30. PubMed ID: 19695678
[TBL] [Abstract][Full Text] [Related]
8. Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands.
Nakagawa H; Suzuki N; Hirata Y; Hikiba Y; Hayakawa Y; Kinoshita H; Ihara S; Uchino K; Nishikawa Y; Ijichi H; Otsuka M; Arita J; Sakamoto Y; Hasegawa K; Kokudo N; Tateishi K; Koike K
Proc Natl Acad Sci U S A; 2017 May; 114(19):E3806-E3815. PubMed ID: 28439013
[TBL] [Abstract][Full Text] [Related]
9. Enhancer of zeste homolog 2 (EZH2) regulates tumor angiogenesis and predicts recurrence and prognosis of intrahepatic cholangiocarcinoma.
Nakagawa S; Okabe H; Ouchi M; Tokunaga R; Umezaki N; Higashi T; Kaida T; Arima K; Kitano Y; Kuroki H; Mima K; Nitta H; Imai K; Hashimoto D; Yamashita YI; Chikamoto A; Baba H
HPB (Oxford); 2018 Oct; 20(10):939-948. PubMed ID: 29759640
[TBL] [Abstract][Full Text] [Related]
10. Genetics of hepatobiliary carcinogenesis.
Nault JC; Zucman-Rossi J
Semin Liver Dis; 2011 May; 31(2):173-87. PubMed ID: 21538283
[TBL] [Abstract][Full Text] [Related]
11. Multiple cellular origins and molecular evolution of intrahepatic cholangiocarcinoma.
Wei M; Lü L; Lin P; Chen Z; Quan Z; Tang Z
Cancer Lett; 2016 Sep; 379(2):253-61. PubMed ID: 26940139
[TBL] [Abstract][Full Text] [Related]
12. Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis.
Sasaki M; Yamaguchi J; Itatsu K; Ikeda H; Nakanuma Y
J Pathol; 2008 Jun; 215(2):175-83. PubMed ID: 18393368
[TBL] [Abstract][Full Text] [Related]
13. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
[TBL] [Abstract][Full Text] [Related]
14. Comment on: isolation and characterization of tumorigenic extrahepatic cholangiocarcinoma cells with stem cell-like properties.
Gradilone A; Gazzaniga P; Raimondi C; Aglianò AM; Frati L
Int J Cancer; 2011 Apr; 128(8):1997-8. PubMed ID: 20568108
[No Abstract] [Full Text] [Related]
15. Anatomic and molecular pathology of intrahepatic cholangiocarcinoma.
Nakanuma Y; Harada K; Ishikawa A; Zen Y; Sasaki M
J Hepatobiliary Pancreat Surg; 2003; 10(4):265-81. PubMed ID: 14598145
[TBL] [Abstract][Full Text] [Related]
16. Intrahepatic cholangiocarcinoma: current management and emerging therapies.
Rahnemai-Azar AA; Weisbrod AB; Dillhoff M; Schmidt C; Pawlik TM
Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):439-449. PubMed ID: 28317403
[TBL] [Abstract][Full Text] [Related]
17. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma.
Zheng T; Hong X; Wang J; Pei T; Liang Y; Yin D; Song R; Song X; Lu Z; Qi S; Liu J; Sun B; Xie C; Pan S; Li Y; Luo X; Li S; Fang X; Bhatta N; Jiang H; Liu L
Hepatology; 2014 Mar; 59(3):935-46. PubMed ID: 24037855
[TBL] [Abstract][Full Text] [Related]
18. Epigenome Remodeling in Cholangiocarcinoma.
O'Rourke CJ; Lafuente-Barquero J; Andersen JB
Trends Cancer; 2019 Jun; 5(6):335-350. PubMed ID: 31208696
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanism of cholangiocarcinoma carcinogenesis.
Maemura K; Natsugoe S; Takao S
J Hepatobiliary Pancreat Sci; 2014 Oct; 21(10):754-60. PubMed ID: 24895231
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of PDZK1IP1, EEF1A2 and RPL41 genes in intrahepatic cholangiocarcinoma.
Yang G; Zong H
Mol Med Rep; 2016 Jun; 13(6):4786-90. PubMed ID: 27082702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
